No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
KROS241220C20000
- 0.70
- -1.30-65.00%
15min DelayClose Dec 13 16:00 ET
2.00High0.45Low
2.00Open2.00Pre Close159 Volume0 Open Interest20.00Strike Price16.35KTurnover118.86%IV9.93%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type0.3897Delta0.1241Gamma24.30Leverage Ratio-0.0888Theta0.0013Rho9.47Eff Leverage0.0100Vega
Intraday
- 5D
- Daily
News
Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank
Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84
Truist Financial Issues a Buy Rating on Keros Therapeutics (KROS)